{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T14:11:51Z","timestamp":1777558311148,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2013,1,3]],"date-time":"2013-01-03T00:00:00Z","timestamp":1357171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes and Vascular Disease Research"],"published-print":{"date-parts":[[2013,5]]},"abstract":"<jats:p>The low-density lipoprotein cholesterol (LDL-C) lowering efficacy of switching to ezetimibe\/simvastatin (EZ\/S) 10\/20 mg versus doubling the run-in statin dose (to simvastatin 40 mg or atorvastatin 20 mg) or switching to rosuvastatin 10 mg in subjects with cardiovascular disease (CVD) and diabetes was assessed. Endpoints included percentage change in LDL-C and percentage of patients achieving LDL-C &lt;70 mg\/dL. Significantly greater reductions in LDL-C occurred when switching to EZ\/S versus statin doubling in the overall population and in subjects treated with simvastatin 20 mg or atorvastatin 10 mg (all p &lt; 0.001). The LDL-C reduction was numerically greater when switching to EZ\/S versus switching to rosuvastatin ( p = 0.060). Significantly more subjects reached LDL-C &lt;70 mg\/dL with EZ\/S (54.5%) versus statin doubling (27.0%) or rosuvastatin (42.5%) in the overall population (all p &lt; 0.001) and within each stratum (all p &lt; 0.001). Switching to EZ\/S provided significantly greater reductions in LDL-C versus statin doubling and significantly greater achievement of LDL-C targets versus statin doubling or switching to rosuvastatin.<\/jats:p>","DOI":"10.1177\/1479164112465212","type":"journal-article","created":{"date-parts":[[2013,1,3]],"date-time":"2013-01-03T21:11:41Z","timestamp":1357247501000},"page":"277-286","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":21,"title":["A comparison of efficacy and safety of an ezetimibe\/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease"],"prefix":"10.1177","volume":"10","author":[{"given":"Jeffrey B","family":"Rosen","sequence":"first","affiliation":[{"name":"Clinical Research of South Florida, Coral Gables, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose G","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Hospital CIMA San Jose, Escazu, Costa Rica"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valdis","family":"Pirags","sequence":"additional","affiliation":[{"name":"University of Latvia, Riga, Latvia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hella","family":"Vides","sequence":"additional","affiliation":[{"name":"Viljandi Hospital, Viljandimaa, Estonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E","family":"Hanson","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachid","family":"Massaad","sequence":"additional","affiliation":[{"name":"MSD Belgium, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail","family":"McPeters","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Brudi","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Triscari","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,1,3]]},"reference":[{"key":"bibr1-1479164112465212","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807233390404"},{"key":"bibr2-1479164112465212","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812033392314"},{"key":"bibr3-1479164112465212","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13636-7"},{"key":"bibr4-1479164112465212","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052187"},{"key":"bibr5-1479164112465212","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-9018"},{"key":"bibr6-1479164112465212","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486"},{"key":"bibr7-1479164112465212","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.06.028"},{"key":"bibr8-1479164112465212","doi-asserted-by":"publisher","DOI":"10.1016\/S0828-282X(09)70715-9"},{"key":"bibr9-1479164112465212","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/eurheartj\/ehm124","volume":"28","author":"Ryden L","year":"2007","journal-title":"Eur Heart J"},{"key":"bibr10-1479164112465212","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X132721"},{"key":"bibr11-1479164112465212","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2009.05.003"},{"key":"bibr12-1479164112465212","doi-asserted-by":"publisher","DOI":"10.4065\/81.12.1579"},{"key":"bibr13-1479164112465212","first-page":"538","volume":"17","author":"Furman A","year":"2011","journal-title":"Am J Manag Care"},{"key":"bibr14-1479164112465212","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02022.x"},{"key":"bibr15-1479164112465212","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.606806"},{"key":"bibr16-1479164112465212","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.03.079"},{"key":"bibr17-1479164112465212","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.09.076"},{"key":"bibr18-1479164112465212","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.366"},{"key":"bibr19-1479164112465212","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.08.038"},{"key":"bibr20-1479164112465212","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury (2011). http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm256581.htm"}],"container-title":["Diabetes and Vascular Disease Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1479164112465212","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1479164112465212","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1479164112465212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:22:02Z","timestamp":1777400522000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1479164112465212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["10.1177\/1479164112465212"],"URL":"https:\/\/doi.org\/10.1177\/1479164112465212","relation":{},"ISSN":["1479-1641","1752-8984"],"issn-type":[{"value":"1479-1641","type":"print"},{"value":"1752-8984","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,3]]}}}